Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Leerink Partners Initiates Coverage On Nanobiotix with Outperform Rating, Announces Price Target of $11

Author: Benzinga Newsdesk | December 08, 2023 10:04am
Leerink Partners analyst Jonathan Chang initiates coverage on Nanobiotix (NASDAQ:NBTX) with a Outperform rating and announces Price Target of $11.

Posted In: NBTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist